1 Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, Italy
2 Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain
3 Department of Hematooncology, University Hospital Ostrava, Czech Republic
4 Department of Hematooncology, Faculty of Medicine, University of Ostrava, Czech Republic
5 School of Science, National and Kapodistrian University of Athens, Greece
6 Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, USA
7 Hospital Universitario Salamanca, Spain
8 Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
9 Clinical Genomics and Therapeutics Division, Translational Genomics Research Institute, Phoenix, USA
10 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Italy
11 Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Italy
12 Hematology Department, University Hospital Hôtel-Dieu, Nantes, France
13 Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit, The Netherlands
14 HOVON Foundation, Rotterdam, The Netherlands
15 European Myeloma Network, Italy
16 Unité de Génomique du Myélome, University Hospital, IUCT-Oncopole, CRCT, Toulouse, France
17 Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Greece
18 Department of Medicine, Korea University, Seoul, Korea
1 Department of Internal Medicine, Hematology and Oncology, University Medicine Oldenburg, Germany
2 Department of Hematology and Oncology, University Hospital of Schleswig-Holstein, University of Lübeck, Germany and Universitäres Cancer Center Schleswig-Holstein, Germany
3 Institute of Chemistry and Metabolomics, University of Lübeck, Germany
4 University Medical Center Hamburg-Eppendorf, Oncology Center, Department for Radiotherapy and Radio-Oncology, Germany
1 Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
2 Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Czech Republic
3 Department of Biology, School of Science, National and Kapodistrian University of Athens, Greece
4 Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, Italy
5 Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain
6 Hospital Universitario,Salamanca, Spain
7 Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, the Netherlands
8 Department of Clinical Therapeutics School of Medicine, National and Kapodistrian University of Athens, Greece
9 Hospital Universitario 12 De Octubre, Madrid, Spain
10 Department of Precision and Regenerative Medicine and Ionian Area,"Aldo Moro" University School of Medicine, and Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy
11 Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Torino, Italy
12 Hospital Clínic de Barcelona, Spain
13 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Italy
14 HOVON Foundation, Rotterdam, the Netherlands
15 Hematology Department, University Hospital Hôtel-Dieu, Nantes, France
16 Hematology and Bone Marrow Transplant Unit, Azienda Socio-Sanitaria Territoriale-Papa Giovanni XXIII, Bergamo, Italy
17 Department of Hematology, Theageneio Cancer Hospital, Thessaloniki, Greece
18 Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Czech Republic
19 Department of Hematology, ASST Spedali Civili di Brescia, Italy
20 Unité de Génomique du Myélome, University Hospital, IUCT-Oncopole, CRCT, Toulouse, France
First match: Background. Idecabtagene vicleucel (ide-cel) is the first anti-BCMA CAR-T approved for refractory multiple myeloma (MM). Although pivotal trials have demonstrated it ...
First match: Introduction. CAR-T and bispecific antibody treatment for RRMM show promising clinical activity, but most pts relapse. Clinical data indicate that serial and/or prol ...
First match: ... rform drug sensitivity testing and generate an actionable result. CD138+ plasma cells were isolated from bone marrow, blood (if circulating plasma cells were present ...
First match: ... ) has recently been enriched by the introduction of chimeric antigen receptor T-cells (CAR-T). Since their approval stemmed from controlled clinical trials, real-wor ...
1 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Italy
2 Department of Medical and Surgical Sciences
3 (DIMEC), University of Bologna, Italy
4 Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, University of Milan, Italy
5 AOSS Antonio e Biagio e Cesare Arrigo-SC Ematologia, Alessandria, Italy
6 ASST Papa Giovanni XXIII, Bergamo – SC Ematologia, Italy
7 Ematologia e Terapie cellulari, IRCCS Ospedale Policlinico San Martino, Genova, Italy
8 Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy
9 Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
10 Dipartimento Oncologico "La Maddalena", UOC di Oncoematologia e TMO, Palermo, Italy
11 Hematology Division, Pisa University Hospital, Department of Clinical and Experimental Medicine, University of Pisa, Italy
12 Stem Cell Transplantation and Cellular Therapies Unit, Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy
13 Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
14 Department of Translational and Precision Medicine, Hematology Azienda Policlinico Umberto I Sapienza University of Rome, Italy
15 AOU Città della Salute e della Scienza di Torino and the Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy
16 Clinica Ematologica ed Unità di Terapie Cellulari, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy
17 Hematology Unit, San Bortolo Hospital, Vicenza, Italy
First match: ... linked to treatment resistance and poor outcomes. The mechanisms driving plasma cells to escape the bone marrow and infiltrate extramedullary sites remain unclear. T ...
First match: Background. CAR T-cells and bispecific antibodies (BsAbs) (T cell-redirecting therapies, TCRT) have revolutionized the treatment of relapsed/refractory multiple myel ...
First match: ... threatening organ dysfunction. Treatment (tx) is mostly directed against plasma cells (PCs) and focuses on stopping production of amyloid-forming light chains. Darat ...
First match: ... was refractory to venetoclax. Three patients relapsed after academic anti-BCMA CAR-T. Additional therapies included ixazomib (2), carfilzomib (1), elotuzumab (1) an ...
First match: ... ith acute-onset diarrhea and abdominal pain, starting median three months after CAR-T therapy.1 It is less recognized that this type of colitis can also occur after ...
First match: ... erapeutic target for MM as the receptor is highly expressed on malignant plasma cells; it has little to no expression on non-plasma cell immune populations and limit ...
First match: Introduction. Cilta-cel is manufactured using autologous T cells, whose quality attributes are the main driver of out-of-specification (OOS) manufacturing results. P ...
First match: ... isms that sustain this state and for developing strategies to eliminate dormant cells and ultimately cure MM. Methods. We established and compared in vitro condition ...
First match: ... amples (1 pLOT, n=56; 2 pLOT, n=61; ≥3 pLOT, n=131). At apheresis, CD4+ naïve T cells were higher with 1 or 2 pLOT vs ≥3 pLOT; no difference was found with 3–4 vs 5– ...
First match: ... lquetamab or elranatamab according to institutional practice. All patients were CAR-T naïve, and a subset had prior BCMA exposure with belantamab mafodotin. Data col ...
First match: ... linical outcomes, but molecular mechanisms underlying adaptive resistance of MM cells to PI-induced stress remain incompletely understood. Ribosome collisions (RCs) ...
First match: ... ely. Among patients with prior anti-BCMA TCRT (n=33 [35.5%]), 12 received prior CAR-T and 23 received prior bispecific antibody (BsAb) therapy. For prior CAR-T and p ...
First match: ... is a plasma cell dyscrasia characterized by the clonal proliferation of plasma cells, which is associated with a significantly increased risk of both thrombotic and ...
